SCHEMBL6159652

SCHEMBL6159652

COc1cc([C@@H]2OC[C@@H](c3cc(OC)c(OC)c(OC)c3)O2)cc(OC)c1OC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTAFR P25105 6/20 0.62
ACHE P22303 4/20 0.54
PTPN1 P18031 2/20 0.54
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
MAPK3 P27361 1/20 0.47
MAPK1 P28482 1/20 0.47
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41
TUBB3 Q13509 1/20 0.41
TUBB2A Q13885 1/20 0.41
TUBB8 Q3ZCM7 1/20 0.41
TUBA3E Q6PEY2 1/20 0.41
TUBA1A Q71U36 1/20 0.41
TUBA1C Q9BQE3 1/20 0.41
TUBB6 Q9BUF5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7060824 1.00 PTAFR (0.62) PTAFRACHEPTPN1MEN1KMT2A
SCHEMBL7060832 1.00 PTAFR (0.62) PTAFRACHEPTPN1MEN1KMT2A
SCHEMBL6159671 1.00 PTAFR (0.62) PTAFRACHEPTPN1MEN1KMT2A
SCHEMBL6159663 1.00 PTAFR (0.62) PTAFRACHEPTPN1MEN1KMT2A
SCHEMBL6822928 0.82 PTAFR (0.69) PTAFRACHEPTPN1MEN1KMT2A
SCHEMBL13414990 0.77 ACHE (0.54) PTAFRACHEPTPN1MEN1KMT2A
SCHEMBL11101046 0.77 ACHE (0.58) PTAFRACHEPTPN1MEN1KMT2A
SCHEMBL10456245 0.77 PTAFR (1.00) PTAFRACHEPTPN1MEN1KMT2A
SCHEMBL7018006 0.77 PTAFR (1.00) PTAFRACHEPTPN1MEN1KMT2A
SCHEMBL7018004 0.77 PTAFR (1.00) PTAFRACHEPTPN1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032713-A1 Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-02-10 US claimed
US-20040028756-A1 Platelet-activated factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-02-12 US claimed
WO-2003082199-A2 PLATELET-ACTIVATING FACTOR ANTAGONISTS AS ANALGESIC, ANTI-INFLAMMATORY, UTERINE CONTRACTION INHIBITING, AND ANTI-TUMOR AGENTS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2003-10-09 WO claimed
US-20050032713-A1 Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-02-10 US disclosed
US-20040028756-A1 Platelet-activated factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-02-12 US disclosed
WO-2003082199-A2 PLATELET-ACTIVATING FACTOR ANTAGONISTS AS ANALGESIC, ANTI-INFLAMMATORY, UTERINE CONTRACTION INHIBITING, AND ANTI-TUMOR AGENTS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2003-10-09 WO disclosed
US-20030190368-A1 METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-10-09 US disclosed
EP-0875247-B1 Method for controlling the plasma level of lipoproteins TNO (NL) 2003-05-28 EP disclosed
US-6444664-B1 ANTAGONIST OF PLATELET ACTIVATING FACTOR; BENZO- OR THIENOTRIAZOLO-DIAZEPINE OR BENZODIAZEPINE DERIVATIVE NEDERLANDSE ORGANISATIE VOOR TOEGEPAST - NATUURWETEN SCHAPPELIJK ONDERZOEK (TNO) (NL) 2002-09-03 US disclosed
EP-0875247-A1 Method for controlling the plasma level of lipoproteins NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) 1998-11-04 EP disclosed
US-5631246-A INCREASING LEVELS OF VON WILLEBRAND FACTOR AND/OR BLOOD FACTOR VIII THE CANADIAN RED CROSS SOCIETY (CA) 1997-05-20 US disclosed
WO-1994012667-A1 INHIBITORS OF ARACHIDONIC ACID METABOLITES FOR PREVENTING NEUROLOGICAL DAMAGE THE UNITED STATES DEPARTMENT OF THE ARMY (US) 1994-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030190368-A1 METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES SERPINB1, PLAT, SERPINE1 PTAFR 72/4885ACHE 1004/4885PTPN1 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.